COMMUNIQUÉ DE PRESSE publié le 26/06/2023 à 17:31, il y a 1 année 2 mois Spexis announces the results of its Annual General Meeting 2023
COMMUNIQUÉ DE PRESSE publié le 07/06/2023 à 07:30, il y a 1 année 3 mois Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances
COMMUNIQUÉ DE PRESSE publié le 30/05/2023 à 07:15, il y a 1 année 3 mois Spexis provides business update and announces financial results for the full year 2022
COMMUNIQUÉ DE PRESSE publié le 28/04/2023 à 07:20, il y a 1 année 4 mois Spexis has received temporary approval of an extension until 31 of May 2023 for the disclosure obligation in connection with the publication and the filing of the annual report 2022.
COMMUNIQUÉ DE PRESSE publié le 18/04/2023 à 07:15, il y a 1 année 5 mois Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
COMMUNIQUÉ DE PRESSE publié le 08/02/2023 à 07:20, il y a 1 année 7 mois Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
COMMUNIQUÉ DE PRESSE publié le 25/01/2023 à 12:56, il y a 1 année 7 mois Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
COMMUNIQUÉ DE PRESSE publié le 09/01/2023 à 07:15, il y a 1 année 8 mois Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
Publié le 18/09/2024 à 18:45, il y a 8 heures 28 minutes Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Publié le 18/09/2024 à 18:45, il y a 8 heures 28 minutes Capital increase following the allocation of free shares to EuropaCorp employees
Publié le 18/09/2024 à 17:40, il y a 9 heures 34 minutes Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.
Publié le 18/09/2024 à 23:10, il y a 4 heures 4 minutes Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Publié le 18/09/2024 à 23:00, il y a 4 heures 14 minutes Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Publié le 18/09/2024 à 21:15, il y a 5 heures 59 minutes New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Publié le 18/09/2024 à 21:00, il y a 6 heures 14 minutes Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Publié le 18/09/2024 à 16:30, il y a 10 heures 44 minutes Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Publié le 18/09/2024 à 19:11, il y a 8 heures 3 minutes EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Publié le 18/09/2024 à 18:45, il y a 8 heures 29 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 18/09/2024 à 18:31, il y a 8 heures 42 minutes EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Publié le 18/09/2024 à 18:13, il y a 9 heures 1 minute BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Publié le 18/09/2024 à 17:21, il y a 9 heures 52 minutes EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share